<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04963933</url>
  </required_header>
  <id_info>
    <org_study_id>CLD-262</org_study_id>
    <nct_id>NCT04963933</nct_id>
  </id_info>
  <brief_title>A Medical Device to Treat Brain Aneurysms</brief_title>
  <official_title>Treatment of Ruptured and Unruptured Wide-Neck Aneurysms With Nautilusâ„¢ Device Assisted Occlusion (TORNADO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EndoStream Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EndoStream Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An aneurysm is a bulge in a blood vessel caused by a weakness in the blood vessel wall,&#xD;
      usually where it branches. As blood passes through the weakened blood vessel, the blood&#xD;
      pressure causes a small area to bulge outwards like a balloon. Most brain aneurysms only&#xD;
      cause noticeable symptoms if they burst (rupture). This leads to an extremely serious&#xD;
      condition known as a subarachnoid hemorrhage, where bleeding caused by the ruptured aneurysm&#xD;
      can cause extensive brain damage and symptoms.&#xD;
&#xD;
      The study aims to evaluate the safety and effectiveness of a medical device to treat brain&#xD;
      aneurysms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be treated with the Nautilus, then will be followed up for up to 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>3-6 months</time_frame>
    <description>The rate of participants experiencing death or stroke in treated vascular territory measured using the NIH stroke scale within 3- 6 months follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Probable benefit</measure>
    <time_frame>3-6 months</time_frame>
    <description>Rate of stable, successful aneurysm occlusion measured using the Raymond Roy Occlusion Classification at 3-6 months follow-up</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cerebral Aneurysm</condition>
  <arm_group>
    <arm_group_label>Patients treated with the device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with the Nautilus will be followed up</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nautilus endovascular device</intervention_name>
    <description>Patients will be treated with the Nautilus Endovascular device followed by treatment follow up for up to 6 months</description>
    <arm_group_label>Patients treated with the device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        * Patients who present with intracranial aneurysm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        * Unstable neurological deficit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hadas Abalia-Didi</last_name>
    <phone>+972 - 50-9064868</phone>
    <email>Hadas@endostream.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel HaShomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

